Gil, Robert JBil, JacekGrundeken, Maik JIñigo Garcia, Luis AVassilev, DobrinKern, AdamPawłowski, TomaszWykrzykowska, Joanna JSerruys, Patrick W2025-01-072025-01-072016https://hdl.handle.net/10668/25647The aim of this study was to assess prospectively the effectiveness and safety of a new version of the dedicated bifurcation BiOSS stent, the sirolimus-eluting BiOSS LIM, for the treatment of distal left main (LM) stenosis. This was a prospective international registry which enrolled patients with NSTE-ACS or stable angina. Provisional T-stenting was the mandated strategy. The primary endpoint was the cumulative rate of cardiac death, myocardial infarction (MI) and target lesion revascularisation (TLR) at 12 months. Twelve-month quantitative coronary angiography endpoints included late lumen loss and percent diameter stenosis. A total of 74 patients with distal LM stenosis were enrolled. Seventy-three of the 74 patients (aged 67±9 years, 23% women, 20.3% NSTE-ACS, SYNTAX score 22.4±4.4) were successfully treated with the BiOSS LIM stent, with additional side branch placement of regular DES in 11 patients (14.9%). Periprocedural MI occurred in one (1.4%) patient. The 12-month MACE rate was 9.5% without cardiac death or definite stent thrombosis. TLR and MI rates were 6.8% (n=5) and 2.7% (n=2), respectively. The use of the BiOSS LIM dedicated bifurcation stent for the treatment of distal LM stenosis was feasible and safe, with promising long-term clinical effectiveness.enAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryConstriction, PathologicCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsFemaleHumansMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesRegistriesSirolimusTimeTreatment Outcomeresearch article26465375open access10.4244/EIJY15M10_051969-6213http://api.eurointervention.com/v1/articles/12218/download/pdf